PRKD1 and cancer: In order to examine if this activation of PKD was important for the viral life cycle, we tested a well-validated chemical inhibitor of PKD, namely, CRT0066101, which has previously been studied as a potential cancer chemotherapeutic agent and was well tolerated at doses up to 80 mg/kg of body weight in animal models (48, 51).